NCT07614776
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Recruiting
PHASE3Ages 50+InterventionalTreatmentAmgen
~304 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:ABP 938 8 mgAflibercept (US) 8 mg
At a glance
Recruiting sites
36 of 36 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
Measured over Baseline and Week 12
Conditions
Where it's being run
36 sites across 18 statesCalifornia6
Texas6
South Carolina5
Florida3
Maryland2
Washington2
Colorado1
Connecticut1
Study leadership
- MD · STUDY_DIRECTOR · Amgen
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Men or women ≥ 50 years old, capable of giving signed informed consent
Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)
Total area of CNV (including both classic and occult components) \> 50% of the total lesion area in the SE
The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE
Presence of intra and/or subretinal fluid affecting the central subfield of the SE as identified by SD-OCT attributable to active CNV. The central subfield is defined as a circle with a diameter of 1 mm, centered on the fovea
Exclusion
Total lesion size \> 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye
Scar, fibrosis, or atrophy involving the central subfield in the study eye
Scar or fibrosis involving \> 50% of the total lesion in the study eye
Presence of retinal pigment epithelium tears or rips involving the macula in the study eye
History of any vitreous hemorrhage ≤ 4 weeks (28 days) before randomization in the study
Presence of other causes of CNV, including pathologic myopia (spherical equivalent ≥ 8 diopters negative or axial length ≥ 25 mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study
Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with anti-glaucoma medication) in the study eye
History or clinical evidence of DR, DME, idiopathic autoimmune uveitis, or any other vascular disease affecting the retina, other than nAMD in either eye
Evidence of active extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening or randomization
Uncontrolled blood pressure (defined as systolic \>160 mmHg or diastolic \>95 mmHg). Blood pressure needs to be stable for at least 12 weeks (84 days) prior to screening
Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti VEGF or anti-VEGF/anti-angiopoietin agent) in the SE, or surgery for nAMD in the SE, except dietary supplements or vitamins
History or evidence of any other clinically significant disorder, condition, disease or clinical laboratory abnormality that, in the opinion of the investigator or study medical monitor, if consulted, would pose a risk to participant safety or interfere with the study evaluation or results interpretation
What this trial measures
- Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter scoreBaseline and Week 12